- Home
- POLA vs CANF Comparison
POLA vs CANF Comparison
Compare POLA & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POLA
- CANF
- Stock Information
- Founded
- POLA 1979
- CANF 1994
- Country
- POLA United States
- CANF Israel
- Employees
- POLA N/A
- CANF N/A
- Industry
- POLA Industrial Machinery/Components
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- POLA Miscellaneous
- CANF Health Care
- Exchange
- POLA Nasdaq
- CANF Nasdaq
- Market Cap
- POLA 11.5M
- CANF 9.6M
- IPO Year
- POLA 2016
- CANF N/A
- Fundamental
- Price
- POLA $3.35
- CANF $0.41
- Analyst Decision
- POLA
- CANF Strong Buy
- Analyst Count
- POLA 0
- CANF 3
- Target Price
- POLA N/A
- CANF $10.50
- AVG Volume (30 Days)
- POLA 882.9K
- CANF 269.6K
- Earning Date
- POLA 11-14-2025
- CANF 11-27-2025
- Dividend Yield
- POLA N/A
- CANF N/A
- EPS Growth
- POLA N/A
- CANF N/A
- EPS
- POLA N/A
- CANF N/A
- Revenue
- POLA $11,967,000.00
- CANF $560,000.00
- Revenue This Year
- POLA N/A
- CANF $461.72
- Revenue Next Year
- POLA N/A
- CANF N/A
- P/E Ratio
- POLA N/A
- CANF N/A
- Revenue Growth
- POLA 0.14
- CANF N/A
- 52 Week Low
- POLA $1.53
- CANF $0.41
- 52 Week High
- POLA $5.75
- CANF $2.38
- Technical
- Relative Strength Index (RSI)
- POLA 43.67
- CANF 24.13
- Support Level
- POLA $3.48
- CANF $0.41
- Resistance Level
- POLA $4.25
- CANF $0.43
- Average True Range (ATR)
- POLA 0.44
- CANF 0.02
- MACD
- POLA -0.10
- CANF -0.00
- Stochastic Oscillator
- POLA 3.69
- CANF 3.19
About POLA Polar Power Inc.
Polar Power Inc is engaged in designing, manufacturing, and selling DC power generators, renewable energy, and cooling systems for applications in the telecommunications market and, to a lesser extent, in other markets, including military, electric vehicle, marine, and industrial. The company's products include DC generators, backup DC generators, hybrid power systems, Li-Ion battery systems, Marine DC generators, and others. The company's geographical presence is in the United States, Canada, Australia and South Pacific Islands, Asia, Europe and Middle East, United Kingdom, Other North America, South Africa, and others.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).